ASTRAZENECA PLC (ZEG.DE) Stock Price, Quote, News and Overview
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
ZEG.DE Quote, Performance and Key Statistics
ASTRAZENECA PLC
FRA:ZEG (2/4/2025, 7:00:00 PM)
133.4
-3.25 (-2.38%)
The current stock price of ZEG.DE is 133.4 EUR. In the past month the price increased by 3.37%. In the past year, price increased by 15.45%.
ZEG.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 81.75 | 763.63B | ||
| 1LLY.MI | ELI LILLY & CO | 79.43 | 741.99B | ||
| NOV.DE | NOVO NORDISK A/S-B | 28.87 | 364.05B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.25 | 355.12B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.23 | 354.69B | ||
| 1SAN.MI | SANOFI | 14.78 | 260.95B | ||
| SAN.PA | SANOFI | 14.6 | 257.74B | ||
| SNW.DE | SANOFI | 14.58 | 257.34B | ||
| 1MRKX.MI | MERCK & CO. INC. | 16.39 | 238.80B | ||
| 6MK.DE | MERCK & CO. INC. | 15.1 | 220.08B | ||
| 1PFE.MI | PFIZER INC | 10.24 | 145.02B | ||
| PFE.DE | PFIZER INC | 9.99 | 141.50B |
Related stock screener links
About ZEG.DE
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. The company also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Company Info
ASTRAZENECA PLC
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE GB
Employees: 89900
Company Website: https://www.astrazeneca.com/
Investor Relations: https://www.astrazeneca.com/investor-relations.html
Phone: 442073045000
ZEG.DE FAQ
What is the stock price of ZEG.DE?
The current stock price of ZEG.DE is 133.4 EUR.
What is the symbol for ASTRAZENECA PLC stock?
The exchange symbol of ASTRAZENECA PLC is ZEG and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is ZEG.DE stock listed?
ZEG.DE stock is listed on the Deutsche Boerse Ag exchange.
Is ZEG.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ZEG.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ZEG.DE.
Does ZEG.DE stock pay dividends?
ZEG.DE has a dividend yield of 2.06%. The yearly dividend amount is currently 2.89.
When does ZEG.DE stock report earnings?
ZEG.DE will report earnings on 2025-02-06, before the market open.
What is the Price/Earnings (PE) ratio of ZEG.DE?
The PE ratio for ZEG.DE is 18.22. This is based on the reported non-GAAP earnings per share of 7.32 and the current share price of 133.4 EUR.
ZEG.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE is one of the better performing stocks in the market, outperforming 77.51% of all stocks.
ZEG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. ZEG.DE scores excellent on profitability, but there are some minor concerns on its financial health.
ZEG.DE Financial Highlights
Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 7.32. The EPS increased by 5.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.11% | ||
| ROA | 6.17% | ||
| ROE | 16.3% | ||
| Debt/Equity | 0.79 |
ZEG.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to ZEG.DE. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 15.68% and a revenue growth 15.89% for ZEG.DE